Otitis Externa News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Catalyst Biosciences (CBIO) and Novus Therapeutics (NVUS ... - The Ledger Gazette



The Ledger Gazette
 
Catalyst Biosciences (CBIO) and Novus Therapeutics (NVUS ... 
The Ledger Gazette
Catalyst Biosciences (NASDAQ: CBIO) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends ...

and more » 


Ask the Vet: When should I spay or neuter my kitten? How do I treat ... - Arizona Daily Sun



Arizona Daily Sun
 
Ask the Vet: When should I spay or neuter my kitten? How do I treat ... 
Arizona Daily Sun
Q: My dog was just treated for an ear infection last month and now he has another one! Why did it come back? Was it not treated appropriately the first.

and more » 


Smarter testing for anemia and infections | Contemporary Pediatrics - ModernMedicine



Smarter testing for anemia and infections | Contemporary Pediatrics 
ModernMedicine
1. I see a fair number of children with mild anemia who do not respond to iron and have normal indices, red cell distribution width (RDW), iron/ferritin levels, reticulocyte counts, electrophoresis, and smears. I consider them in general to have ...

and more » 


Infections of the ear - The New Times



Infections of the ear 
The New Times
Malignant or necrotising otitis externa is a potentially fatal condition developing in diabetic or immune depressed subjects. It progresses insidiously over weeks to months, causing severe pain, discharge and marked redness of the ear. It can spread to ...

 


Head to Head Contrast: Novus Therapeutics (NVUS) vs. Catalyst Biosciences (CBIO) - StockNewsTimes



Head to Head Contrast: Novus Therapeutics (NVUS) vs. Catalyst Biosciences (CBIO) 
StockNewsTimes
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

and more » 


Synlogic (NASDAQ:SYBX) and Novus Therapeutics (NVUS) Critical Comparison - The Ledger Gazette



The Ledger Gazette
 
Synlogic (NASDAQ:SYBX) and Novus Therapeutics (NVUS) Critical Comparison 
The Ledger Gazette
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

 


Biogen (BIIB) vs. Novus Therapeutics (NVUS) Critical Contrast ... - Week Herald



Week Herald
 
Biogen (BIIB) vs. Novus Therapeutics (NVUS) Critical Contrast ... 
Week Herald
Novus Therapeutics (NASDAQ: NVUS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership ...
Biogen Inc. - BIIB - Stock Price Today - Zacks Zacks
SEC FORM 4 - SEC.gov SEC.gov
SEC FORM 4 - SEC.gov SEC.gov
SEC.gov 
all 197 news articles » 


Novus Therapeutics (NASDAQ:NVUS) & Catalyst Biosciences (CBIO ... - Week Herald



Novus Therapeutics (NASDAQ:NVUS) & Catalyst Biosciences (CBIO ... 
Week Herald
Novus Therapeutics (NASDAQ: NVUS) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership ...

and more » 


Novus Therapeutics (NVUS) & Catalyst Biosciences (CBIO) Head ... - The Ledger Gazette



Week Herald
 
Novus Therapeutics (NVUS) & Catalyst Biosciences (CBIO) Head ... 
The Ledger Gazette
Novus Therapeutics (NASDAQ: NVUS) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends ...
Head to Head Survey: Catalyst Biosciences (CBIO) and Novus ... Week Herald

all 3 news articles » 


Otonomy Announces FDA Acceptance of OTIPRIOŽ Supplemental New Drug Application Filing for Acute Otitis Externa - GlobeNewswire (press release)



Otonomy Announces FDA Acceptance of OTIPRIOŽ Supplemental New Drug Application Filing for Acute Otitis Externa 
GlobeNewswire (press release)
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that its ...

and more »